Canarick Robert 4

What Happened Robert Canarick, a director of Integrated Biopharma, was granted a derivative award for 50,000 shares on 2026-06-24. The Form 4 reports an acquisition price of $0.00 (total reported value $0). This was an award/grant (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: June 24, 2026; Form 4 filed June 25, 2026 (appears timely).
• Reported transaction: Grant/Award (transaction code A) of 50,000 derivative securities at $0.00; reported acquisition value $0.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award vests in four equal installments of 12,500 each on Sept 30, 2026; Dec 31, 2026; Mar 31, 2027; and June 30, 2027.
• No indication in the filing that shares were immediately sold or that a 10b5-1 plan or tax-withholding was used.

Context This is a time‑vested derivative compensation grant to a board member and should be viewed as routine director compensation rather than a direct buy/sell signal. The filing lists the award as a derivative that becomes exercisable/vests in scheduled installments; because the reported acquisition value is $0, no cash payment at grant was recorded in the Form 4.